Iterum Therapeutics PLC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Iterum Therapeutics reported increased net losses and significant cash burn, raising substantial doubt about its ability to continue as a going concern despite the recent U.S. commercial launch of ORLYNVAH.
Iterum Therapeutics reports continued net losses and substantial doubt about its ability to continue as a going concern, while preparing for the commercial launch of ORLYNVAH by end of August 2025.
10-Q: Iterum Therapeutics Faces Going Concern Doubts Despite ORLYNVAH Approval, Explores Strategic Options
Iterum Therapeutics reports Q1 2025 results, highlighting ongoing efforts to commercialize ORLYNVAH while addressing concerns about its ability to continue as a going concern.
Iterum Therapeutics announced its Q3 2024 financial results, highlighted by the FDA approval of ORLYNVAH and ongoing strategic evaluation.
10-Q: Iterum Therapeutics Reports Q2 2024 Results, Faces Going Concern Uncertainty Amidst Strategic Review
Iterum Therapeutics reports a net loss of $12.1 million for the first half of 2024 and expresses substantial doubt about its ability to continue as a going concern due to insufficient cash reserves.
Iterum Therapeutics reports a net loss of $7.1 million for the first quarter of 2024 and expresses substantial doubt about its ability to continue as a going concern due to insufficient cash to fund operations for the next 12 months.